Mechanism of Fufang Congrong Yizhi Capsules in treatment of mild cognitive impairment based on network pharmacology

Author: Qin HAN ¹ ; Xiao-Yu XU ¹ ; Yi-Fei GENG ¹ ; Xiao-Bo SUN ¹ ; Yun LUO ¹ ; Jing-Jing LIU ²
Author Information

1. Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences
2. Lei Yun Shang Pharmaceutical Group Corporation Limited
Publication Type:Journal Article
Keywords: A(3; Bcl2/Bax; Fufang Congrong Yizhi Capsules; mild cognitive impairment; network pharmacology; PI3K/AKT signaling pathway
From: Chinese Pharmacological Bulletin 2024;40(2):334-343
CountryChina
Language:Chinese
Abstract: Aim To predict the mechanism of Fufang Congrong Yizhi Capsules (FCYC) in the treatment of mild cognitive impairment (MCI) by network pharmacology method, and further validate it in combination with cellular experiments. Methods TCMSP, Gene-Cards, OMIM and TTD databases, Chinese Pharmacopoeia and related literature were used to screen the active ingredients of FCYC and the targets of MCI treatment. The TCM-compound-target-disease network and PPI of intersection targets were constructed, and the GO and KEGG analysis were performed by the Ehamb bioinformation platform. GO and KEGG analysis were performed through Yihanbo biological information platform. Cell model of MCI was established by PC-12 injury induced by Aβ